OJEMDA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ojemda, and what generic alternatives are available?
Ojemda is a drug marketed by Day One Biopharms and is included in two NDAs. There are two patents protecting this drug.
This drug has forty-nine patent family members in twenty-seven countries.
The generic ingredient in OJEMDA is tovorafenib. One supplier is listed for this compound. Additional details are available on the tovorafenib profile page.
DrugPatentWatch® Generic Entry Outlook for Ojemda
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be August 4, 2031. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OJEMDA?
- What are the global sales for OJEMDA?
- What is Average Wholesale Price for OJEMDA?
Summary for OJEMDA
International Patents: | 49 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Patent Applications: | 79 |
What excipients (inactive ingredients) are in OJEMDA? | OJEMDA excipients list |
DailyMed Link: | OJEMDA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for OJEMDA
Generic Entry Dates for OJEMDA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
FOR SUSPENSION;ORAL |
Generic Entry Dates for OJEMDA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for OJEMDA
OJEMDA is protected by two US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of OJEMDA is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting OJEMDA
Pharmaceutical formulations of a pan-RAF kinase inhibitor and processes for their preparation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compounds useful as Raf kinase inhibitors
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Day One Biopharms | OJEMDA | tovorafenib | FOR SUSPENSION;ORAL | 218033-001 | Apr 23, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Day One Biopharms | OJEMDA | tovorafenib | TABLET;ORAL | 217700-001 | Apr 23, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Day One Biopharms | OJEMDA | tovorafenib | FOR SUSPENSION;ORAL | 218033-001 | Apr 23, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Day One Biopharms | OJEMDA | tovorafenib | TABLET;ORAL | 217700-001 | Apr 23, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for OJEMDA
When does loss-of-exclusivity occur for OJEMDA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 7354
Patent: COMPUESTOS UTILES COMO INHIBIDORES DE LA RAF QUINASA
Estimated Expiration: ⤷ Sign Up
Australia
Patent: 08273002
Patent: Pyrimidine derivatives useful as Raf kinase inhibitors
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0813499
Patent: COMPOSTOS ÚTEIS COMO INIBIDORES DA QUINASE RAF
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 93182
Patent: COMPOSES UTILES EN TANT QU'INHIBITEURS DE LA KINASE RAF (COMPOUNDS USEFUL AS RAF KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 08001933
Patent: Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
Estimated Expiration: ⤷ Sign Up
China
Patent: 1784545
Patent: Compounds useful as raf kinase inhibitors
Estimated Expiration: ⤷ Sign Up
Patent: 4370828
Patent: COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
Patent: 6957314
Patent: 用作RAF激酶抑制剂的嘧啶衍生物 (Compounds useful as Raf kinase inhibitors)
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 31798
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 67489
Patent: COMPOSÉS UTILES EN TANT QU'INHIBITEURS DE LA KINASE RAF (PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 31798
Patent: DÉRIVÉS DE THIAZOLE UTILES DANS LA PRÉPARATION DES INHIBITEURS DE LA KINASE RAF (THIAZOLE INTERMEDIATES USEFUL IN THE PREPARATION OF RAF KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 2835
Patent: נגזרות פירימידין,הרכבים רוקחיים שלהם, תהליך להכנתם ושימושיהם כמעכבי raf קינאז (Pyrimidine derivatives , pharmaceutical compositions thereof, process for their manufacture and uses thereof as raf kinase inhibitors)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 49445
Estimated Expiration: ⤷ Sign Up
Patent: 62622
Estimated Expiration: ⤷ Sign Up
Patent: 10532380
Estimated Expiration: ⤷ Sign Up
Patent: 13256534
Patent: COMPOUNDS USEFUL AS RAF KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
Patent: 15117249
Patent: RAFキナーゼ阻害剤として有用な化合物 (COMPOUND USEFUL AS RAF KINASE INHIBITOR)
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 2352
Patent: PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 92166
Patent: СОЕДИНЕНИЯ, ПОДХОДЯЩИЕ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ RAF (COMPOUNDS SUITABLE FOR USE AS RAF KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Patent: 09149214
Patent: СОЕДИНЕНИЯ, ПОДХОДЯЩИЕ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ RAF
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 0909223
Patent: PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1650140
Estimated Expiration: ⤷ Sign Up
Patent: 1764076
Estimated Expiration: ⤷ Sign Up
Patent: 100033384
Patent: PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS
Estimated Expiration: ⤷ Sign Up
Patent: 160027992
Patent: RAF 카나아제 억제제로서 유용한 화합물 (PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS)
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 35729
Estimated Expiration: ⤷ Sign Up
Patent: 76169
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 44379
Estimated Expiration: ⤷ Sign Up
Patent: 0916467
Patent: Compounds useful as Raf kinase inhibitors
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 1478
Patent: СОЕДИНЕНИЯ, ПОЛЕЗНЫЕ КАК ИНГИБИТОРЫ RAF-КИНАЗЫ;СПОЛУКИ, КОРИСНІ ЯК ІНГІБІТОРИ Raf-КІНАЗИ (COMPOUNDS USEFUL AS INHIBITORS OF RAF PROTEIN KINASE)
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering OJEMDA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 5649445 | ⤷ Sign Up | |
Japan | 2013256534 | COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | ⤷ Sign Up |
Taiwan | I444379 | ⤷ Sign Up | |
Chile | 2008001933 | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. | ⤷ Sign Up |
European Patent Office | 3231798 | DÉRIVÉS DE THIAZOLE UTILES DANS LA PRÉPARATION DES INHIBITEURS DE LA KINASE RAF (THIAZOLE INTERMEDIATES USEFUL IN THE PREPARATION OF RAF KINASE INHIBITORS) | ⤷ Sign Up |
Uruguay | 36046 | FORMULACIONES FARMACÉUTICAS, PROCESOS PARA LA PREPARACIÓN Y MÉTODOS DE USO | ⤷ Sign Up |
Canada | 2693182 | COMPOSES UTILES EN TANT QU'INHIBITEURS DE LA KINASE RAF (COMPOUNDS USEFUL AS RAF KINASE INHIBITORS) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |